MX2020001337A - Formulaciones que comprenden un acido nucleico en una alta concentracion. - Google Patents

Formulaciones que comprenden un acido nucleico en una alta concentracion.

Info

Publication number
MX2020001337A
MX2020001337A MX2020001337A MX2020001337A MX2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A MX 2020001337 A MX2020001337 A MX 2020001337A
Authority
MX
Mexico
Prior art keywords
treatment
nucleic acid
formulations
high concentration
viscosity
Prior art date
Application number
MX2020001337A
Other languages
English (en)
Inventor
Mariana Dimitrova
William J Bennett
Qi Wang
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2020001337A publication Critical patent/MX2020001337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las composiciones de ácido nucleico de baja viscosidad y alta concentración que pueden administrarse mediante múltiples vías parenterales podrían permitir una dosificación menos frecuente que los productos de ácido nucleico que se encuentran presentes en la actualidad en el mercado. En particular, las formulaciones de desfibrotides de baja viscosidad para la administración subcutánea, intramuscular e intraperitoneal son más convenientes para el paciente y/o se administran fuera del entorno hospitalario. Las formulaciones de la invención pueden utilizarse en el tratamiento de numerosas afecciones lo que incluye, por ejemplo, el tratamiento de arteriopatías periféricas, el tratamiento de insuficiencia renal aguda, el tratamiento de isquemia miocárdica aguda y el tratamiento y prevención del síndrome de obstrucción sinusoidal o VOD.
MX2020001337A 2017-08-03 2018-08-03 Formulaciones que comprenden un acido nucleico en una alta concentracion. MX2020001337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540657P 2017-08-03 2017-08-03
PCT/US2018/045152 WO2019028340A1 (en) 2017-08-03 2018-08-03 FORMULATIONS COMPRISING A HIGH CONCENTRATION NUCLEIC ACID

Publications (1)

Publication Number Publication Date
MX2020001337A true MX2020001337A (es) 2020-09-09

Family

ID=63364168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001337A MX2020001337A (es) 2017-08-03 2018-08-03 Formulaciones que comprenden un acido nucleico en una alta concentracion.

Country Status (16)

Country Link
US (2) US20200261489A1 (es)
EP (1) EP3661484A1 (es)
JP (1) JP2020530004A (es)
KR (1) KR20200121780A (es)
CN (1) CN111132663A (es)
AR (1) AR112403A1 (es)
AU (1) AU2018309068A1 (es)
BR (1) BR112020002289A2 (es)
CA (1) CA3071544A1 (es)
CO (1) CO2020001873A2 (es)
IL (1) IL272405A (es)
MX (1) MX2020001337A (es)
SG (1) SG11202000952PA (es)
TW (1) TW201909904A (es)
WO (1) WO2019028340A1 (es)
ZA (1) ZA202000676B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014031934B1 (pt) 2012-06-22 2021-05-04 Gentium S.R.L. método com base em euglobulina para determinar a atividade biológica de defibrotide
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US20190328765A1 (en) 2018-04-30 2019-10-31 Gentium S.R.L. Methods for treating patients having sinusoidal obstruction syndrome
WO2020118165A1 (en) 2018-12-07 2020-06-11 Jazz Pharmaceuticals Ireland Limited Subcutaneous delivery of high concentration formulations
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
EP4110287A1 (en) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
WO2021212055A1 (en) 2020-04-17 2021-10-21 Jazz Pharmaceuticals Ireland Limited Defibrotide treatment for the prevention of organ rejection and injury
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸
KR20220151414A (ko) * 2021-05-06 2022-11-15 연세대학교 산학협력단 허혈성 뇌질환 예방 또는 치료용 약학적 조성물
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1170215B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US4693134A (en) 1985-06-20 1987-09-15 Excelermatic Inc. High-powered vehicle drive train
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
IT1223322B (it) 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
ATE311907T1 (de) 1999-06-08 2005-12-15 Gentium Spa Anwendung von komplexen von kationischen liposomen und polydeoxyribonukleotiden wie arzneimitteln
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1325962A1 (en) 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
WO2005089503A2 (en) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
CA2598072C (en) 2005-03-03 2016-05-03 Massimo Iacobelli Formulations with anti-tumour action
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
CN101301306A (zh) * 2008-06-30 2008-11-12 广东天普生化医药股份有限公司 Dft在制备治疗和预防休克药物中的应用
CN101301308A (zh) * 2008-06-30 2008-11-12 广东天普生化医药股份有限公司 Dft在制备治疗和预防弥散性血管内凝血药物中的应用
CN101759767A (zh) 2008-10-23 2010-06-30 湖州来色生物基因工程有限公司 一种双甘氨肽的合成方法
NZ602685A (en) * 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
US8980862B2 (en) 2010-11-12 2015-03-17 Gentium S.P.A. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD)
BR112014031934B1 (pt) 2012-06-22 2021-05-04 Gentium S.R.L. método com base em euglobulina para determinar a atividade biológica de defibrotide
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Also Published As

Publication number Publication date
ZA202000676B (en) 2021-01-27
WO2019028340A1 (en) 2019-02-07
US20200261489A1 (en) 2020-08-20
TW201909904A (zh) 2019-03-16
KR20200121780A (ko) 2020-10-26
AU2018309068A8 (en) 2020-02-27
JP2020530004A (ja) 2020-10-15
BR112020002289A2 (pt) 2020-07-28
SG11202000952PA (en) 2020-02-27
CO2020001873A2 (es) 2020-04-13
IL272405A (en) 2020-03-31
EP3661484A1 (en) 2020-06-10
CA3071544A1 (en) 2019-02-07
CN111132663A (zh) 2020-05-08
AR112403A1 (es) 2019-10-23
AU2018309068A1 (en) 2020-02-20
US20210338707A1 (en) 2021-11-04
WO2019028340A9 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2020001337A (es) Formulaciones que comprenden un acido nucleico en una alta concentracion.
MY191574A (en) Pharmaceutical compositions comprising meloxicam
MA43574A (fr) Compositions ayant des amplificateurs de perméation pour l'administration de médicaments
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
TN2018000056A1 (en) Rapid-acting insulin compositions.
MX2018004834A (es) Metodos para tratar dolor usando dimeros de acetominofeno farmaceuticamente activos enlazados a traves de grupos hidroxilo fenolicos.
PH12020500076A1 (en) Long-acting formulations
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
TN2017000011A1 (en) Aqueous formulation comprising paracetamol and ibuprofen.
NZ723139A (en) Fgf-18 compound dosing regimen
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MD20180049A2 (ro) Compoziţie farmaceutică
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2022013237A (es) Maltodextrinas entrelazadas para el suministro oral de activos biologicos.
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
MD20170071A2 (ro) Compoziţii injectabile de paracetamol
MX2017016978A (es) Composicion farmaceutica de heparinas de bajo peso molecular.
MX2021000312A (es) Composicion farmaceutica que contiene un peptido.
WO2016115442A3 (en) Therapeutic protein formulations
PH12017500345A1 (en) Pharmaceutical composition for the treatment of acute tooth or jaw pain
Sharma Bisphosphonates increase the risk of atrial fibrillation
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα
WO2016164719A3 (en) Methods used to treat cancer